---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-22-000010"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:55:29.384296+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Entrada Therapeutics reports Q2 2022 net loss of $23.2M; cash runway into 2H 2024

## Summary
- Cash, cash equivalents and marketable securities $244.3M as of June 30, 2022, sufficient into 2H 2024.
- Net loss $23.2M vs $9.9M in Q2 2021; R&D $16.2M (up from $6.8M), G&A $7.3M (up from $3.1M).
- On track to file IND for ENTR-601-44 (Duchenne) in Q4 2022; ENTR-701 named as first DM1 clinical candidate.
- Appointed Karla MacDonald as Chief Corporate Affairs Officer.
- Entered collaboration with Myotonic Dystrophy Clinical Research Network for natural history study.

## SEC filing metadata
- accession: 0001689375-22-000010
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937522000010/0001689375-22-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937522000010/trda-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-22-000010
- JSON: https://secwatch.observer/filing/0001689375-22-000010.json
- Plain text: https://secwatch.observer/filing/0001689375-22-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.